RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 101–200 of 999
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Waldman, T. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2010_68 · Cited by 291
“This discovery of “hotspot” mutations is reminiscent of alterations in other oncogenes such as KRAS and BRAF (Bos et al. 1987; Davies et al. 2002; Rajagopalan et al. 2002).”
Backgroundvan Krieken, J. H. J. M., Jung, A., Kirchner, T., Carneiro, F., Seruca, R., Bosman, F. T., Quirke, P., Fléjou, J. F., Plato Hansen, T., de Hertogh, G., et al. (2008) · Virchows Archiv · doi:10.1007/s00428-008-0665-y · Cited by 289
“In MSI colorectal carcinoma, BRAF mutations occur independently of KRAS mutations and provide proliferation and survival signals through activation of several signaling pathways [44, 45].”
BackgroundRahmani, M., Davis, E. M., Bauer, C., Dent, P., & Grant, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506551200 · Cited by 288
Oncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
“…reported in several tumours and the recent discovery of activated B-raf alleles in colon cancer cells, melanoma cells, and certain other cancer cells supports the importance of this signal transduction pathway in cancer progression and/or maintenance (Davies et al., 2002; Rajagopalan et al., 2002).”
BackgroundYang, S., Farraye, F. A., Mack, C., Posnik, O., & O’Brien, M. J. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000141404.56839.6a · Cited by 286
“Both BRAF and KRAS are proto-oncogenes that interact in tandem in the growth factor-activated RAS-RAF-MEK-ERKMAP kinase signaling pathway.(3,14) This is a primordial intracellular molecular network that plays an important role in the control of cell differentiation, proliferation, survival, and apoptosis.”
BackgroundBRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.
Wang, L., Cunningham, J. M., Winters, J. L., Guenther, J. C., French, A. J., Boardman, L. A., Burgart, L. J., McDonnell, S. K., Schaid, D. J., & Thibodeau, S. N. (2003) · PubMed · Cited by 282
Serrated Polyps and Colorectal Cancer: New Pathway to Malignancy
Noffsinger, A. E. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092317 · Cited by 282
Missense mutations of the BRAF gene in human lung adenocarcinoma.
Naoki, K., Chen, T. H., Richards, W. G., Sugarbaker, D. J., & Meyerson, M. M. (2002) · PubMed · Cited by 287
New insight into BRAF mutations in cancer
Dhomen, N., & Marais, R. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.005 · Cited by 278
Sinicrope, F. A., Mahoney, M. R., Smyrk, T. C., Thibodeau, S. N., Warren, R. S., Bertagnolli, M. M., Nelson, G. D., Goldberg, R. M., Sargent, D. J., & Alberts, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.9591 · Cited by 279
“The BRAF oncogene encodes a serine/ threonine kinase and is a downstream effector of the Ras/Raf/MAPK signaling pathway.(8,9) BRAF or KRAS mutations predict nonresponse to anti–epidermal growth factor receptor antibody therapy in metastatic CRCs, although only KRAS has been validated.”
BackgroundMutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
Fransen, K. (2003) · Carcinogenesis · doi:10.1093/carcin/bgh049 · Cited by 268
“Our results therefore support the study made by Rajagopalan et al. ( 9 ), who also observed a correlation between BRAF mutations and MSI.”
BackgroundResultInfluentialTherapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Trovisco, V., Soares, P., Preto, A., de Castro, I. V., Lima, J., Castro, P., Máximo, V., Botelho, T., Moreira, S., Meireles, A. M., et al. (2005) · Virchows Archiv · doi:10.1007/s00428-005-1236-0 · Cited by 253
“It had been previously detected in rare cases of melanoma and colorectal carcinoma [3, 18] and, by our group, in two follicular adenomas of the thyroid [11, 22].”
Sartore-Bianchi, A., Di Nicolantonio, F., Nichelatti, M., Molinari, F., De Dosso, S., Saletti, P., Martini, M., Cipani, T., Marrapese, G., Mazzucchelli, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007287 · Cited by 259
“BRAF is the principal downstream effector of KRAS [17,18] and its oncogenic V600E mutation is mutually exclusive with KRAS mutations in CRCs [ 19 ].”
BackgroundSelf-citationFecher, L. A., Amaravadi, R. K., & Flaherty, K. T. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f5271c · Cited by 249
Ogino, S., Brahmandam, M., Cantor, M., Namgyal, C., Kawasaki, T., Kirkner, G., Meyerhardt, J. A., Loda, M., & Fuchs, C. S. (2006) · Modern Pathology · doi:10.1038/modpathol.3800482 · Cited by 252
“9 BRAF mutations in colorectal carcinoma were reported to occur more commonly in those cases with high degree of microsatellite instability (MSI-H)”
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
French, A. J., Sargent, D. J., Burgart, L. J., Foster, N. R., Kabat, B. F., Goldberg, R., Shepherd, L., Windschitl, H. E., & Thibodeau, S. N. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1489 · Cited by 251
BRAF and NRAS mutations in melanoma and melanocytic nevi
Poynter, J. N., Elder, J. T., Fullen, D. R., Nair, R. P., Soengas, M. S., Johnson, T. M., Redman, B., Thomas, N. E., & Gruber, S. B. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222600.73179.f3 · Cited by 245
Jass, J. R., Baker, K., Zlobec, I., Higuchi, T., Barker, M., Buchanan, D., & Young, J. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02466.x · Cited by 244
“It is well established that BRAF and KRAS mutation rarely occur in the same colorectal neoplasm.(12,16,30) Furthermore, BRAF mutations are much more typical of serrated polyps than adenomas.”
BackgroundLi, S., Li, L., Zhu, Y., Huang, C., Qin, Y., Liu, H., Ren-Heidenreich, L., Shi, B., Ren, H., Chu, X., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.210 · Cited by 243
“Interestingly, our data showed that KRAS and BRAF V600E mutations are mutually exclusive, which agrees with Rajagopalan et al (2002) that the BRAF mutation occurs only in tumours that do not carry KRAS mutations, as KRAS and BRAF provide an equivalent or at least redundant oncogenic stimulus in…”
BackgroundRahmani, M., Davis, E. M., Crabtree, T. R., Habibi, J. R., Nguyen, T. K., Dent, P., & Grant, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-06 · Cited by 241
“MEK1/2-ERK1/2 module occurs in a high percentage (30%) of human cancers (12, 42, 48 , 57) provided a rationale for attempting to disrupt this pathway as a candidate anticancer strategy.”
BackgroundPrecision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Self-citationIn ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Mismatch repair deficient colorectal cancer in the era of personalized treatment
Hewish, M., Lord, C. J., Martin, S. A., Cunningham, D., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.18 · Cited by 235
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer
Calhoun, E. S., Jones, J. B., Ashfaq, R., Adsay, V., Baker, S. J., Valentine, V., Hempen, P. M., Hilgers, W., Yeo, C. J., Hruban, R. H., et al. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63485-2 · Cited by 232
Sengupta, N., Yau, C., Sakthianandeswaren, A., Mouradov, D., Gibbs, P., Suraweera, N., Cazier, J.-B., Polanco-Echeverry, G., Ghosh, A., Thaha, M., et al. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-1 · Cited by 231
Tie, J., Lipton, L., Desai, J., Gibbs, P., Jorissen, R. N., Christie, M., Drummond, K. J., Thomson, B. N. J., Usatoff, V., Evans, P. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1720 · Cited by 217
Klingbiel, D., Saridaki, Z., Roth, A. D., Bosman, F. T., Delorenzi, M., & Tejpar, S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu499 · Cited by 231
“We confirm the high frequency of BRAF mutations in the MSI-H population [25].”
ResultKumar, R., Angelini, S., Snellman, E., & Hemminki, K. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22225.x · Cited by 229
Tie, J., Gibbs, P., Lipton, L., Christie, M., Jorissen, R. N., Burgess, A. W., Croxford, M., Jones, I., Langland, R., Kosmider, S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25555 · Cited by 227
“0001).(5,7,24) Given that KRAS mutation testing is increasingly incorporated into routine practice and that BRAF mutations occur almost exclusively in KRAS wild-type tumors, KRAS wild-type status could be further used to enrich the population of patient for testing for the presence of BRAF mutations (Table 2); for exa…”
BackgroundDi Gion, P., Kanefendt, F., Lindauer, A., Scheffler, M., Doroshyenko, O., Fuhr, U., Wolf, J., & Jaehde, U. (2011) · Clinical Pharmacokinetics · doi:10.2165/11593320-000000000-00000 · Cited by 224
Raphael, B. J., Dobson, J. R., Oesper, L., & Vandin, F. (2014) · Genome Medicine · doi:10.1186/gm524 · Cited by 218
“Examples include BRAF and KRAS [108] (in the RAS-RAF signaling pathway) and APC and CTNNB1 (in the β -catenin signaling pathway), both in colorectal cancer [109], and TP53 and MDM2 in ovarian cancer [7].”
BackgroundFahey, T. J. (2006) · Yearbook of Surgery · doi:10.1016/s0090-3671(08)70420-8 · Cited by 218
Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics
Lagerstedt Robinson, K., Liu, T., Vandrovcova, J., Halvarsson, B., Clendenning, M., Frebourg, T., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Peltomaki, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk051 · Cited by 216
Self-citationNagasaka, T., Sasamoto, H., Notohara, K., Cullings, H. M., Takeda, M., Kimura, K., Kambara, T., MacPhee, D. G., Young, J., Leggett, B. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.154 · Cited by 217
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Bradley, W. D., Lee, R. J., Schostack, K., Simcox, M. E., Kopetz, S., Heimbrook, D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2941 · Cited by 216
“Furthermore, KRAS and BRAF mutations appear to be mutually exclusive in colorectal tumors, highlighting the importance of BRAF mutations in tumorigenesis for a subset of patients (5, 14).”
Rad, R., Cadiñanos, J., Rad, L., Varela, I., Strong, A., Kriegl, L., Constantino-Casas, F., Eser, S., Hieber, M., Seidler, B., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.05.014 · Cited by 216
“Third, murine and human intestinal tumors with KRAS mutations are mostly MSI-stable or MSI-low (Noffsinger, 2009; Bennecke et al., 2010), whereas BRAF mutant human tumors are frequently MSI-high (Rajagopalan et al., 2002).”
BackgroundInfluentialMutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer
Artale, S., Sartore-Bianchi, A., Veronese, S. M., Gambi, V., Sarnataro, C. S., Gambacorta, M., Lauricella, C., & Siena, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7286 · Cited by 192
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
Zhang, L. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.080062 · Cited by 213
Colorectal Cancer Biomarkers: Where Are We Now?
Gonzalez-Pons, M., & Cruz-Correa, M. (2015) · BioMed Research International · doi:10.1155/2015/149014 · Cited by 209
Clarke, C. N., & Kopetz, S. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 207
“KRAS and NRAS mutations are present in 50% of CRCs and their therapeutic significance is well defined (1-3).”
BackgroundInfluentialCragg, M. S., Jansen, E. S., Cook, M., Harris, C., Strasser, A., & Scott, C. L. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35437 · Cited by 207
Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis
Eckert, L. B., Repasky, G. A., Ülkü, A. S., McFall, A., Zhou, H., Sartor, C. I., & Der, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0396 · Cited by 207
Microsatellite instability: an update
Yamamoto, H., & Imai, K. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1474-0 · Cited by 247
BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar, R., Angelini, S., Czene, K., Sauroja, I., Hahka‐Kemppinen, M., Pyrhönen, S. O., & Hemminki, K. (2003) · PubMed · Cited by 205
McGivern, A., Wynter, C. V. A., Whitehall, V. L. J., Kambara, T., Spring, K. J., Walsh, M. D., Barker, M. A., Arnold, S., Simms, L. A., Leggett, B. A., et al. (2004) · Familial Cancer · doi:10.1023/b:fame.0000039861.30651.c8 · Cited by 206
“Recently, activating mutations in the BRAF protooncogene have been associated with MSI-H tumours in general [16], and subsequently with the sporadic subset in particular [17–19], providing a further avenue for the distinction between familial and sporadic MSI-H tumours.”
BackgroundHeinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203
Mitofusin 2 Triggers Vascular Smooth Muscle Cell Apoptosis via Mitochondrial Death Pathway
Guo, X., Chen, K.-H., Guo, Y., Liao, H., Tang, J., & Xiao, R.-P. (2007) · Circulation Research · doi:10.1161/circresaha.107.157644 · Cited by 200
Three molecular pathways model colorectal carcinogenesis in Lynch syndrome
Ahadova, A., Gallon, R., Gebert, J., Ballhausen, A., Endris, V., Kirchner, M., Stenzinger, A., Burn, J., von Knebel Doeberitz, M., Bläker, H., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31300 · Cited by 195
Karagkounis, G., Torbenson, M. S., Daniel, H. D., Azad, N. S., Diaz, L. A., Donehower, R. C., Hirose, K., Ahuja, N., Pawlik, T. M., & Choti, M. A. (2013) · Cancer · doi:10.1002/cncr.28347 · Cited by 193
Microarray expression profiling in melanoma reveals a BRAF mutation signature
Pavey, S., Johansson, P., Packer, L., Taylor, J., Stark, M., Pollock, P. M., Walker, G. J., Boyle, G. M., Harper, U., Cozzi, S.-J., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207563 · Cited by 183
“…of papillary thyroid cancers (Cohen et al., 2003; Fukushima et al., 2003; Kimura et al., 2003), 5–18% of colorectal carcinomas (Davies et al., 2002; Rajagopalan et al., 2002; Yuen et al., 2002) and 2–3% of lung cancers (Brose et al., 2002; Davies et al., 2002; Naoki et al., 2002; Cohen et al.,…”
BackgroundSerrated neoplasia—role in colorectal carcinogenesis and clinical implications
IJspeert, J. E. G., Vermeulen, L., Meijer, G. A., & Dekker, E. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.73 · Cited by 190
Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
Funkhouser, W. K., Lubin, I. M., Monzon, F. A., Zehnbauer, B. A., Evans, J. P., Ogino, S., & Nowak, J. A. (2012) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.11.001 · Cited by 189
Honecker, F., Wermann, H., Mayer, F., Gillis, A. J. M., Stoop, H., van Gurp, R. J. L. M., Oechsle, K., Steyerberg, E., Hartmann, J. T., Dinjens, W. N. M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8623 · Cited by 188
Jacob, K., Albrecht, S., Sollier, C., Faury, D., Sader, E., Montpetit, A., Serre, D., Hauser, P., Garami, M., Bognar, L., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605179 · Cited by 186
“In keeping with these data, only oncogenic BRAF mutations have been implicated in tumours of epithelial (Rajagopalan et al, 2002) and neuroectodermal origin (Brose et al, 2002; Pollock et al, 2003).”
BackgroundEGFR Signaling in Colorectal Carcinoma
Krasinskas, A. M. (2011) · Pathology Research International · doi:10.4061/2011/932932 · Cited by 184
Tejpar, S., Bertagnolli, M., Bosman, F., Lenz, H.-J., Garraway, L., Waldman, F., Warren, R., Bild, A., Collins-Brennan, D., Hahn, H., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0233 · Cited by 185
Koorstra, J.-B. M., Hustinx, S. R., Offerhaus, G. J. A., & Maitra, A. (2008) · Pancreatology · doi:10.1159/000123838 · Cited by 183
Pathology and genetics of thyroid carcinoma
DeLellis, R. A. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20700 · Cited by 181
“The RAF proteins are serine/threonine protein kinases that play critical roles in cell proliferation, differentiation, and apoptosis by signaling along the mitogen-activated protein kinase pathway (MAPK) [26,27] Mammalian cells express three isoforms of RAF threonine kinase that have been designated ARAF, BRAF, and CR…”
BackgroundInfluentialKRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors
Miranda, C., Nucifora, M., Molinari, F., Conca, E., Anania, M. C., Bordoni, A., Saletti, P., Mazzucchelli, L., Pilotti, S., Pierotti, M. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2230 · Cited by 181
Mercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
“cancers in vivo , the situation may well be more complex as B-Raf mutations are detected in a high proportion of benign melanocytic lesions (nevi) and premalignant colon polyps in which the cells are thought to be senescent (9, 18, 41, 42).”
BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas
Lima, J., Trovisco, V., Soares, P., Máximo, V., Magalhães, J., Salvatore, G., Santoro, M., Bogdanova, T., Tronko, M., Abrosimov, A., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032224 · Cited by 181
Qi Li, W., Kawakami, K., Ruszkiewicz, A., Bennett, G., Moore, J., & Iacopetta, B. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-2 · Cited by 179
Domingo, E., Niessen, R. C., Oliveira, C., Alhopuro, P., Moutinho, C., Espín, E., Armengol, M., Sijmons, R. H., Kleibeuker, J. H., Seruca, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208569 · Cited by 177
“…in the exon 15 of BRAF, a member of the RAF family of kinases, has been recently reported in colorectal tumors with high microsatellite instability (MSIH), and was found associated to a defective mismatch repair (MMR) system (Davies et al., 2002; Rajagopalan et al., 2002; Oliveira et al., 2003).”
BackgroundKRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
Oliveira, C., Velho, S., Moutinho, C., Ferreira, A., Preto, A., Domingo, E., Capelinha, A. F., Duval, A., Hamelin, R., Machado, J. C., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1209758 · Cited by 178
“In sporadic colorectal cancer (CRC), oncogenic mutations affecting KRAS and BRAF occur in about 30 and 10% of the cases, respectively (Rajagopalan et al., 2002; Yuen et al., 2002; Brink et al., 2003; Wang et al., 2003; Oliveira et al., 2003, 2004, 2005).”
BackgroundResultInfluentialRosty, C., Hewett, D. G., Brown, I. S., Leggett, B. A., & Whitehall, V. L. J. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-012-0720-y · Cited by 178
“These mutations are mutually exclusive and demonstrate a striking specificity for serrated polyp subtype [19, 32, 33].”
BackgroundBRAF V600E mutation-specific antibody: A review
Ritterhouse, L. L., & Barletta, J. A. (2015) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2015.02.010 · Cited by 172
“exclusive in many of these tumors, suggesting that they have a similar tumorigenic effect.(1,3,5,6)”
BackgroundKawaguchi, Y., Kopetz, S., Newhook, T. E., De Bellis, M., Chun, Y. S., Tzeng, C.-W. D., Aloia, T. A., & Vauthey, J.-N. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0863 · Cited by 174
“However, RAS and BRAF mutations are almost always mutually exclusive (44), the number of patients with BRAFmutation in our study was small, and BRAFmutation was not identified as a risk factor for RFS in a Cox proportional hazards model.”
BackgroundLoukopoulos, P., Kanetaka, K., Takamura, M., Shibata, T., Sakamoto, M., & Hirohashi, S. (2004) · Pancreas · doi:10.1097/00006676-200410000-00004 · Cited by 172
Hyperplastic and Serrated Polyps of the Colorectum
O'Brien, M. J. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.08.007 · Cited by 172
Yeh, J. J., Routh, E. D., Rubinas, T., Peacock, J., Martin, T. D., Shen, X. J., Sandler, R. S., Kim, H. J., Keku, T. O., & Der, C. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0972 · Cited by 172
“The frequent mutational activation of two key effectors with validated roles in Ras-mediated oncogenesis, encoded by BRAF and PIK3CA, support the importance of aberrant effector signaling in mutant K-Ras function in colorectal cancer (7, 8).”
BackgroundJones, R. P., Sutton, P. A., Evans, J. P., Clifford, R., McAvoy, A., Lewis, J., Rousseau, A., Mountford, R., McWhirter, D., & Malik, H. Z. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.37 · Cited by 166
“%) in Western populations (Rajagopalan et al, 2002) and it is well recognised that the respective malignancy of the codon 12 and 13 mutations is independent of BRAF (Colussi et al, 2013).”
BackgroundGarcia-Aguilar, J., Chen, Z., Smith, D. D., Li, W., Madoff, R. D., Cataldo, P., Marcet, J., & Pastor, C. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31822b8cfa · Cited by 171
“0575 CCND1 = AA and MTHFR = TT 32 (24) 1 (3) 31 (31) 0.”
Mouse models of colorectal cancer: Past, present and future perspectives
Bürtin, F., Mullins, C. S., & Linnebacher, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i13.1394 · Cited by 170
Lack of BRAF mutations in uveal melanoma.
Rimoldi, D., Salvi, S., Líénard, D., Lejeune, F. J., Speiser, D. E., Zografos, L., & Cerottini, J. (2003) · PubMed · Cited by 169
Geldanamycin and its anti-cancer activities
Fukuyo, Y., Hunt, C. R., & Horikoshi, N. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.07.010 · Cited by 167
Obesity and colorectal cancer: molecular features of adipose tissue
Martinez-Useros, J., & Garcia-Foncillas, J. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0772-5 · Cited by 167
Mutant proteins as cancer-specific biomarkers
Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J., Papadopoulos, N., Kopelovich, L., Maitra, A., Matthaei, H., Eshleman, J. R., Hruban, R. H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019203108 · Cited by 168
“The mutations identified by SRM in all five samples were identical to those previously found in these tumors (32).”
ResultSelf-citationThe Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedLoughrey, M. B., Waring, P. M., Tan, A., Trivett, M., Kovalenko, S., Beshay, V., Young, M.-A., McArthur, G., Boussioutas, A., & Dobrovic, A. (2007) · Familial Cancer · doi:10.1007/s10689-007-9124-1 · Cited by 165
“Following the identification of somatic BRAF mutations in a subset of CRC, it was recognised that these mutations were mostly associated with tumours displaying MSI [24, 25].”
BackgroundInfluentialSomatic alterations in the human cancer genome
Weir, B., Zhao, X., & Meyerson, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.004 · Cited by 166
Mutations of PIK3CAin gastric adenocarcinoma
Li, V. S. W., Wong, C. W., Chan, T. L., Chan, A. S. W., Zhao, W., Chu, K.-M., So, S., Chen, X., Yuen, S. T., & Leung, S. Y. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-29 · Cited by 164
“A prominent example is the mutually exclusive occurrence of the BRAF hotspot mutation (V600E) and KRAS mutations in colorectal cancer [24,25].”
Ikenoue, T., Hikiba, Y., Kanai, F., Tanaka, Y., Imamura, J., Imamura, T., Ohta, M., Ijichi, H., Tateishi, K., Kawakami, T., et al. (2003) · PubMed · Cited by 164
Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer
Lemieux, E., Cagnol, S., Beaudry, K., Carrier, J., & Rivard, N. (2015) · Oncogene · doi:10.1038/onc.2014.416 · Cited by 164
Simi, L., Pratesi, N., Vignoli, M., Sestini, R., Cianchi, F., Valanzano, R., Nobili, S., Mini, E., Pazzagli, M., & Orlando, C. (2008) · American Journal of Clinical Pathology · doi:10.1309/lwdy1axhxuulnvhq · Cited by 164
Hyperplastic polyps and colorectal cancer: is there a link?
Jass, J. R. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00284-2 · Cited by 163
Toyooka, S., Tokumo, M., Shigematsu, H., Matsuo, K., Asano, H., Tomii, K., Ichihara, S., Suzuki, M., Aoe, M., Date, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2625 · Cited by 163
KRAS and BRAF: drug targets and predictive biomarkers
Vakiani, E., & Solit, D. B. (2011) · The Journal of Pathology · doi:10.1002/path.2796 · Cited by 162
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Molinari, F., Felicioni, L., Buscarino, M., De Dosso, S., Buttitta, F., Malatesta, S., Movilia, A., Luoni, M., Boldorini, R., Alabiso, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3137 · Cited by 159
“All KRAS mutated cases were BRAF wild type and vice-versa, confirming data from the literature (32).”
BackgroundSelf-citationLi, R., Zhang, L., Jia, L., Duan, Y., Li, Y., Bao, L., & Sha, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100893 · Cited by 159
“colorectal carcinomas, papillary thyroid carcinomas, serous ovarian carcinomas and lung cancers [21,33].”
BackgroundKarapetis, C. S., Jonker, D., Daneshmand, M., Hanson, J. E., O'Callaghan, C. J., Marginean, C., Zalcberg, J. R., Simes, J., Moore, M. J., Tebbutt, N. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0606 · Cited by 159
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas
Knobbe-Thomsen, C. B., REIFENBERGER, J., & Reifenberger, G. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0929-9 · Cited by 156
“None of these tumors showed NRAS mutations, which would be in line with findings in other tumors indicating that NRAS and BRAF mutations are mutually exclusive [7, 20, 22, 24].”
ResultMurphy, D. A., Makonnen, S., Lassoued, W., Feldman, M. D., Carter, C., & Lee, W. M. F. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050711 · Cited by 154
BRAF as a potential therapeutic target in melanoma and other malignancies
Tuveson, D. A., Weber, B. L., & Herlyn, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00189-2 · Cited by 157
“Colorectal cancers harbor mutant BRAF alleles in 4%–10% of the tumors (Rajagopalan et al., 2002;Yuen et al., 2002), with the majority of these mutations being BRAFV599E.”
BackgroundInfluentialYoon, H. H., Tougeron, D., Shi, Q., Alberts, S. R., Mahoney, M. R., Nelson, G. D., Nair, S. G., Thibodeau, S. N., Goldberg, R. M., Sargent, D. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3140 · Cited by 156
“on the nature of the underlying genetic instability (38, 39).”
B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms
Tran, N. H., Wu, X., & Frost, J. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501185200 · Cited by 154
The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154
Self-citationBRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency
Oliveíra, C., Pinto, M., Duval, A., Louis‐Brennetot, C., Domingo, E., Espín, E., Armengol, M., Yamamoto, H., Hamelin, R., Seruca, R., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1207061 · Cited by 151
“Even though K-Ras and BRAF mutations have been described as alternative events in these tumors (Raja- gopalan et al., 2002), we found two concomitant mutations in two Japanese cases of our collection (Figure 3).”
BackgroundInfluential
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.